New hope for rare sarcomas: Triple-Drug combo targets tumors
NCT ID NCT05253131
First seen Jan 08, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study tests a combination of three drugs (selumetinib, ZEN-3694, and durvalumab) in adults with sarcomas, including a rare nerve tumor called MPNST. The goal is to see if the combination is safe and can shrink or stabilize tumors. The study is for people whose cancer has not responded to other treatments or cannot be removed by surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NF1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.